Ophthalmic Surg Lasers Imaging Retina. 2020 Jul 1;51(7):402-406. doi: 10.3928/23258160-20200702-05.
To describe a safe and dependable protocol for intravitreal injections for the treatment of retinopathy of prematurity (ROP).
SAFER is an acronym used to describe the injection protocol and includes (S)hort needle (4-mm length), (A)ntiseptic/antibiotic (5% to 10% topical betadine), (F)ollowup (48 to 72 hours post-injection), (E)xtra attention to detail (clean environment, injection site 0.75 mm to 1.0 mm posterior to limbus), and (R)echeck (1 to 2 weeks following injection and until mature vascularization or laser).
No cases of cataract formation, endophthalmitis, or vitreous hemorrhage using this technique were reported in a recent retrospective chart review.
This protocol is a safe way to inject anti-vascular endothelial growth factor and to monitor ROP progression following injection. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:402-406.].
描述一种安全可靠的治疗早产儿视网膜病变(ROP)的玻璃体内注射方案。
SAFER 是描述注射方案的缩写,包括(S)短针(4 毫米长)、(A)消毒/抗生素(5%至 10%的局部聚维酮碘)、(F)随访(注射后 48 至 72 小时)、(E)注意细节(清洁环境,注射部位位于后缘 0.75 至 1.0 毫米处)和(R)复查(注射后 1 至 2 周并直至血管成熟或激光治疗)。
在最近的回顾性图表审查中,没有报告使用这种技术引起白内障形成、眼内炎或玻璃体积血的病例。
该方案是一种安全的注射抗血管内皮生长因子的方法,并可在注射后监测 ROP 的进展。[眼科手术激光成像视网膜。2020;51:402-406。]。